Dr. Grey AI

Ziconotide (Prialt)

Peptide

Ziconotide is a synthetic 25-amino acid peptide derived from omega-conotoxin MVIIA found in Conus magus marine snail venom. FDA-approved in 2004 for severe chronic pain refractory to other treatments. Administered intrathecally via implanted pump. RCTs showed significant pain reduction (14.7% vs 7.2% placebo). Unique non-opioid mechanism with no tolerance development.

Quick Answer

What it is

Ziconotide is a synthetic 25-amino acid peptide derived from omega-conotoxin MVIIA found in Conus magus marine snail venom. FDA-approved in 2004 for severe chronic pain refractory to other treatments.

Key findings

  • Grade A: Pain Intensity Reduction (Chronic pain)
  • Grade A: Long-term Pain Control (Chronic pain)
  • Grade A: Opioid-Refractory Pain (Chronic pain)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Ziconotide (Prialt)

Quick Facts: Ziconotide (Prialt)

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:8
  • Grade A Findings:3
  • Grade B Findings:3
  • Key Effect:Chronic pain
A3
B3
C2
D0
1 conditions · 8 outcomes

Detailed Outcomes

A
Pain Intensity Reduction
RCT: 14.7% VASPI improvement vs 7.2% placebo (P=0.036). Significant improvement with slow titration protocol.
moderate↓Improves
A
Long-term Pain Control
Stable pain scores over 3 years in 644-patient study. No evidence of tolerance development. 119 patients treated >360 days.
moderate↓Improves
A
Opioid-Refractory Pain
Effective in patients refractory to intrathecal morphine and other opioids. Provides option when tolerance develops to opioids.
moderate↓Improves
B
Quality of Life
Improved quality of life reported in patients with treatment-resistant chronic pain in long-term studies.
moderate↑Improves
B
Function and Mobility
Improvements in physical function observed alongside pain reduction in clinical trials.
small↑Improves
B
Anti-Cancer Activity
9 human trials support this finding. Human clinical trial data available.
moderate↑Improves
C
Liver Protection
7 preclinical studies support this finding. Primarily preclinical evidence.
small↑Improves
C
Safety/Tolerability
5 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
small↑Improves